CN106282113B - 一种利用无血清培养基通过转分化获得神经细胞的方法 - Google Patents
一种利用无血清培养基通过转分化获得神经细胞的方法 Download PDFInfo
- Publication number
- CN106282113B CN106282113B CN201510289740.6A CN201510289740A CN106282113B CN 106282113 B CN106282113 B CN 106282113B CN 201510289740 A CN201510289740 A CN 201510289740A CN 106282113 B CN106282113 B CN 106282113B
- Authority
- CN
- China
- Prior art keywords
- cells
- serum
- medium
- cell
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 210000002569 neuron Anatomy 0.000 title claims abstract description 35
- 239000012679 serum free medium Substances 0.000 title claims description 36
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 239000001963 growth medium Substances 0.000 claims abstract description 26
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 25
- 239000000654 additive Substances 0.000 claims abstract description 15
- 239000004017 serum-free culture medium Substances 0.000 claims abstract description 15
- 239000003102 growth factor Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 210000003061 neural cell Anatomy 0.000 claims description 42
- 239000002609 medium Substances 0.000 claims description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 30
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 19
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 15
- 229930003268 Vitamin C Natural products 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 14
- 230000000996 additive effect Effects 0.000 claims description 12
- 239000007640 basal medium Substances 0.000 claims description 11
- 210000004498 neuroglial cell Anatomy 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 230000010261 cell growth Effects 0.000 claims description 10
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 6
- 239000007758 minimum essential medium Substances 0.000 claims description 6
- 239000002771 cell marker Substances 0.000 claims description 5
- 238000010166 immunofluorescence Methods 0.000 claims description 5
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 claims description 3
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 claims description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 claims description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 3
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 claims description 3
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 claims description 3
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 210000004504 adult stem cell Anatomy 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 9
- 108091023040 Transcription factor Proteins 0.000 abstract description 4
- 102000040945 Transcription factor Human genes 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 210000001178 neural stem cell Anatomy 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 small molecule compound Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101150009249 MAP2 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
N2 | B27 | bFGF | EGF | 维生素C | |
最优化 | 1% | 0% | 20ng/ml | 0ng/ml | 50μg/ml |
1 | 0% | 2% | 20ng/ml | 0ng/ml | 50μg/ml |
2 | 1% | 1% | 20ng/ml | 0ng/ml | 50μg/ml |
3 | 1% | 0% | 0ng/ml | 20ng/ml | 50μg/ml |
4 | 1% | 0% | 10ng/ml | 20ng/ml | 50μg/ml |
5 | 1% | 0% | 20ng/ml | 0ng/ml | 10μg/ml |
6 | 1% | 0% | 20ng/ml | 0ng/ml | 20μg/ml |
7 | 1% | 0% | 20ng/ml | 0ng/ml | 100μg/ml |
8 | 1% | 0% | 20ng/ml | 0ng/ml | 200μg/ml |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510289740.6A CN106282113B (zh) | 2015-05-29 | 2015-05-29 | 一种利用无血清培养基通过转分化获得神经细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510289740.6A CN106282113B (zh) | 2015-05-29 | 2015-05-29 | 一种利用无血清培养基通过转分化获得神经细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106282113A CN106282113A (zh) | 2017-01-04 |
CN106282113B true CN106282113B (zh) | 2020-01-03 |
Family
ID=57655378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510289740.6A Active CN106282113B (zh) | 2015-05-29 | 2015-05-29 | 一种利用无血清培养基通过转分化获得神经细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106282113B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107151656A (zh) * | 2017-05-10 | 2017-09-12 | 中国科学院广州生物医药与健康研究院 | 一种提高体细胞向神经细胞转分化效率的方法 |
CN107254443B (zh) * | 2017-07-28 | 2020-03-13 | 广州赛莱拉干细胞科技股份有限公司 | 一种促进骨髓间充质干细胞向神经元分化的诱导培养基和诱导方法 |
CN110343660A (zh) * | 2018-04-08 | 2019-10-18 | 生物角(厦门)科技有限公司 | 一种间充质干细胞无血清培养基组合物 |
CN113774023B (zh) * | 2021-09-28 | 2022-11-25 | 中国食品药品检定研究院 | 人诱导多能干细胞诱导分化神经细胞评价模型的构建及其评价药物神经毒性的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102952778A (zh) * | 2011-08-29 | 2013-03-06 | 北京清美联创干细胞科技有限公司 | 一种用吡嗪类小分子化合物诱导干细胞分化的方法 |
CN104004713A (zh) * | 2014-05-14 | 2014-08-27 | 安沂华 | 脐带间充质干细胞诱导培养为神经细胞的方法 |
CN104031882A (zh) * | 2014-06-20 | 2014-09-10 | 上海安集协康生物技术有限公司 | 人神经干细胞体外定向诱导分化为多巴胺能神经元的方法 |
-
2015
- 2015-05-29 CN CN201510289740.6A patent/CN106282113B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102952778A (zh) * | 2011-08-29 | 2013-03-06 | 北京清美联创干细胞科技有限公司 | 一种用吡嗪类小分子化合物诱导干细胞分化的方法 |
CN104004713A (zh) * | 2014-05-14 | 2014-08-27 | 安沂华 | 脐带间充质干细胞诱导培养为神经细胞的方法 |
CN104031882A (zh) * | 2014-06-20 | 2014-09-10 | 上海安集协康生物技术有限公司 | 人神经干细胞体外定向诱导分化为多巴胺能神经元的方法 |
Non-Patent Citations (2)
Title |
---|
Adult human olfactory neural progenitors cultured in defined medium.;Zhang X et al.;《Exp Neurol》;20040430;第186卷(第2期);第112-123页 * |
VEGF转染对MSCs向神经细胞诱导分化的影响;杨丽红;《中华神经外科疾病研究杂志》;20100831;第9卷(第4期);第322-324页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106282113A (zh) | 2017-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2903442T3 (es) | Purificación basada en MACS del epitelio pigmentario de la retina derivado de células madre | |
AU2005205516B2 (en) | Novel culture systems for ex vivo development | |
EP2814948B1 (en) | Feeder-free method for culture of bovine and porcine spermatogonial stem cells | |
Zemelko et al. | Neurogenic potential of human mesenchymal stem cells isolated from bone marrow, adipose tissue and endometrium: a comparative study | |
CN106282113B (zh) | 一种利用无血清培养基通过转分化获得神经细胞的方法 | |
Pimton et al. | Hypoxia enhances differentiation of mouse embryonic stem cells into definitive endoderm and distal lung cells | |
Pang et al. | Neural precursor cells generated from Induced pluripotent stem cells with gelatin sponge-electrospun PLGA/PEG nanofibers for spinal cord injury repair. | |
US20140271584A1 (en) | Methods and Compositions for Direct Reprogramming of Somatic Cells to Stem Cells, and Uses of these Cells | |
Chua et al. | Neural progenitors, neurons and oligodendrocytes from human umbilical cord blood cells in a serum-free, feeder-free cell culture | |
US9290740B2 (en) | Use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells | |
WO2017097007A1 (zh) | 分化培养基及其在制备神经干细胞中的用途 | |
WO2010127555A1 (zh) | 一种干细胞培养方法 | |
Akter et al. | Generation of highly pure motor neurons from human induced pluripotent stem cells | |
JP4576545B2 (ja) | 羊膜由来因子による胚性幹細胞の培養方法 | |
CN112608904B (zh) | 一种高效快速重编程体细胞为神经干细胞的方法及其应用 | |
CN106350490B (zh) | 利用无血清培养基从成纤维细胞中获得神经细胞的方法 | |
Nguyen et al. | Isolation of female germline stem cells from porcine ovarian tissue and differentiation into oocyte-like cells | |
EP1715033A1 (en) | Medium for preparing feeder cells for embryonic stem cells and feeder cells | |
Mollichella et al. | Isolation and Characterization of Cat Olfactory Ecto-Mesenchymal Stem Cells. Animals 2022, 12, 1284 | |
CN117286095A (zh) | 无血清培养基和提高从成纤维细胞中获得心肌细胞的方法 | |
Zhang et al. | Differentiation of human epidermis-derived mesenchymal stem cell-like pluripotent cells into neural-like cells in culture and after transplantation | |
CN117264872A (zh) | 无血清培养基及其在提高转分化肝脏细胞的效率中的应用 | |
CN111440771A (zh) | 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系 | |
Zheng et al. | Effects of glial cell line-derived neurotrophic factor and leukemia-inhibitory factor on the behavior of two calf testis germline stem cell colony types | |
Tsupykov | A protocol for isolation of fetal neural progenitor cells from mouse hippocampus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240229 Address after: Room 104, Building 2, No. 198 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510700 Patentee after: Zhongke Meisi Stem Cell Regenerative Medical Technology (Guangzhou) Co.,Ltd. Country or region after: China Address before: 510530 open source Avenue 190, Science City, Luogang District, Guangzhou, Guangdong. Patentee before: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES Country or region before: China |